Table 1 Baseline characteristics in the denosumab and control groups.
From: Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients
Denosumab n = 28 | Control n = 56 | P value | |
|---|---|---|---|
Demographics | |||
Age (year) | 67.6 ± 11.2 | 71.4 ± 13.4 | 0.18 |
Sex (%), male | 46.4 | 64.3 | 0.11 |
BMI (kg/m2) | 19.7 ± 2.3 | 20.6 ± 2.7 | 0.78 |
DM (%) | 35.7 | 37.5 | 0.87 |
HD vintage (year) | 7.6 (4.3, 16.7) | 8.6 (3.8, 13.6) | 0.83 |
HD duration (h/week) | 12 (12, 13.5) | 12 (12, 12) | 0.50 |
Laboratory data | |||
BUN (mg/dL) | 60.9 ± 13.2 | 57.1 ± 14.9 | 0.22 |
Adj. calcium (mg/dL) | 9.5 ± 0.4 | 9.0 ± 0.5 | 0.0002 |
Phosphate (mg/dL) | 4.9 ± 0.9 | 5.0 ± 1.2 | 0.88 |
Magnesium (mg/dL) | 2.5 ± 0.3 | 2.4 ± 0.3 | 0.12 |
Alb (g/dL) | 3.6 ± 0.3 | 3.4 ± 0.3 | 0.057 |
Hb (g/dL) | 11.5 ± 0.8 | 11.4 ± 1.1 | 0.47 |
ALP (IU/L) | 259 (201, 341.3) | 242 (195.5, 304.5) | 0.53 |
iPTH (pg/mL) | 132.5 (72.3, 178.3) | 142.5 (83.7, 178) | 0.60 |
BAP (µg/L) | 12.7 (10.5, 25.0) | ||
TRACP-5b (mU/dL) | 490.5 (255.7, 659.2) | ||
Bone mineral density | |||
Total hip BMD, g/cm2 | 0.593 (0.555, 0.655) | 0.636 (0.551, 0.696) | 0.21 |
Lumbar spine BMD, g/cm2 | 0.860 (0.765, 1.008) | 0.955 (0.874, 1.069) | 0.015 |
Past history | |||
CVD (%) | 32.1 | 33.9 | 0.86 |
Parathyroidectomy (%) | 0.0 | 3.5 | 0.19 |
Incident fracture (%) | 39.3 | 37.5 | 0.87 |
Medication | |||
CaCO3 (%) | 39.3 | 35.7 | 0.74 |
Phosphate binders (%) | 71.4 | 64.2 | 0.50 |
Vitamin D (%) | 96.4 | 87.5 | 0.15 |
Alfacalcidol (%) | 10.7 | 28.6 | |
Calcitriol (%) | 35.7 | 8.9 | |
Eldecalcitol (%) | 0.0 | 1.8 | |
Maxacalcitol (%) | 50.0 | 48.2 | |
Calcimimetics (%) | 35.7 | 50.0 | 0.21 |
PPI (%) | 53.6 | 64.3 | 0.34 |
Bisphosphonate (Before denosumab) | 10.7 | ||
